Why It Matters
The House Judiciary Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet held a pharmaceutical patent hearing on June 4 that was overtaken in real time by a unanimous Supreme Court ruling, forcing lawmakers and witnesses to grapple simultaneously with live case law and pending legislation. The Trump administration's simultaneous push for pharmaceutical tariffs and most-favored-nation drug pricing creates a direct tension with the hearing's pro-innovation framing, putting the Republican majority in an awkward position.
The Big Picture
The hearing, titled "Medicines and IP: Balancing Innovation and Access," was convened by the Judiciary Subcommittee to examine two pending bills: the ETHIC Act (H.R. 3269), which would limit brand-name drug companies to asserting one patent per cluster in litigation against generics, and the Skinny Labels, Big Savings Act (H.R. 6485), which would protect generic manufacturers from infringement liability when they carve out patented drug uses from their labels. Minutes into the hearing, the Supreme Court issued a unanimous 9-0 decision in Hikma Pharmaceuticals v. Amarin Pharma, ruling that Hikma's skinny-label generic of the cardiovascular drug Vascepa did not induce patent infringement — the precise legal question the Skinny Labels bill was designed to address legislatively.
What They're Saying
The central dispute pitted witnesses who argued the patent system is being gamed against those who said reform would relax innovation.
The sharpest exchange came over biosimilar market exclusivity timelines. Rep. Marie Gluesenkamp Perez (D-WA-3) pressed witnesses on whether biosimilars face 20-plus years of effective exclusivity rather than the 12 to 14 years the statute contemplates. Jamie Simpson, Chief Policy Officer for the Council for Innovation Promotion, held that data shows roughly 14 years. Rachel Goode, Head of Legal and Intellectual Property for Fresenius Kabi, fired back that recent data covering the last decade shows 18 years, which is four years longer than Congress ever contemplated.
Michael Carrier, a Professor of Rutgers Law School, noted the ruling's limits: "If we were to sum up the Hatch-Waxman act in one word, its balance. The problem now is that there isn't balance."
Political Stakes
For Republicans
Rep. Darrell Issa (R-CA), who chairs the subcommittee, is navigating between his long record as an IP protectionist and constituent pressure on drug costs. He has previously led bipartisan opposition to government march-in rights on drug patents, warning such proposals would harm California's life sciences. On the day of the hearing, he co-introduced the Prohibiting Adversarial Patents Act with Rep. Scott Fitzgerald, framing IP protection through a national security lens. The Trump administration's pharmaceutical tariffs, which specifically target branded and patented drugs, further complicate the committee's pro-innovation framing.
For Democrats
Rep. Zoe Lofgren (D-CA), co-sponsor of the Skinny Labels bill, was one of the most prepared members in the room. Lofgren noted that label carve-outs have saved Medicare an estimated $15 billion over five years. Arguing the Supreme Court's ruling, while favorable, leaves the door open for brand companies to relitigate on slightly different facts. Rep. Jamie Raskin (D-MD), the full committee's ranking member, gave a lengthy opening statement grounding the debate in constitutional history and personal experience with medical innovation, but his pre-hearing public communications contained no signal on the topic.
The Bottom Line
Members have five legislative days to submit written follow-up questions to witnesses. Issa asked all four witnesses to respond in writing to a question about whether pharmaceutical manufacturers should be permitted to produce drugs in bonded U.S. facilities for export to markets where patents have expired, a potential onshoring mechanism he framed as a committee priority. No markup date for the ETHIC Act or the Skinny Labels bill has been publicly announced.
A decade of congressional hearings on drug patent policy has produced little structural reform, and this one landed on the same day the Supreme Court handed generic manufacturers a partial win, leaving the question of whether Congress will act or defer to the courts unresolved once again.